MOA and dosing
Discover the science behind once-daily oral control1
MOA=mechanism of action.
PALSONIFY is the first and only nonpeptide SST2-selective agonist1,2
PALSONIFY targets SST2 receptors with potency and precision after efficient GI absorption1
SST2 selective1,4,5
Targets SST2, the primary receptor on
Small nonpeptide molecule designed for once-daily use1,2,4
- Nonpeptide molecule enables efficient gut absorption that’s not possible for peptide-based therapies4,6
- 28-hour half-life supports consistent therapeutic levels with once-daily dosing1,7
PALSONIFY was engineered to provide biochemical and symptom control with the convenience of a once-daily oral1
- GH=growth hormone; GI=gastrointestinal; SST2=somatostatin receptor subtype 2.
Once-daily oral dosing—optimized for convenience1
PALSONIFY gives you the flexibility of titrating your patient’s dose
- After 2 to 4 weeks on PALSONIFY
40 mg once daily, based on IGF-1 levels, increase PALSONIFY dosage to60 mg once daily1 - During initiation period, PALSONIFY may be temporarily reduced to
20 mg once daily if needed, based on tolerability. Once adverse reactions have resolved, resume PALSONIFY40 mg once daily1
- IGF-1=insulin-like growth factor 1.
Dosing instructions
Administration1
- Take with water on an empty stomach at least
6 hours after a meal (eg, after overnight fasting) - Dose at least
1 hour before next meal
Special populations1
- No dose adjustment required for hepatic or renal impairment
Pharmacokinetic profile1
- Has a 28-hour half-life
- Achieves stable concentration within 1 week with consistent daily dosing
Switching from depot injection2,8
- In the PATHFNDR-1 study, patients started PALSONIFY the same week as the next injection would be due
A majority of patients surveyed preferred a once-daily oral medication8,9*
- *In PATHFNDR-1, 60% preferred a once-daily oral (exploratory endpoint). In PATHFNDR-2, 78% preferred a once-daily oral (exploratory endpoint).8,9
Rapid, reliable, and sustained acromegaly control1,10
